CRNX

Crinetics Pharmaceuticals, Inc.

Fundamental data last updated:October 20, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

NASDAQ

County of HQ

US

Next Earnings Date

Pending Announcement

Business Summary

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

 


Analyze CRNX on TradingView

VALUATION

P/E

-7.55

Market Cap ($M USD)

$3.80B

Forward P/E

7.94

PEG

0.04

PRICE TO SALES

210.13

PRICE TO BOOK

2.93

EV / EBITDA

-6.89

5-Year Average P/E

Free Cash Flow Yield

-11.05%

DCF Value

$-7.20

Graham Number

N/A

Price to FCF

-9.05

EV to FCF

-8.89

Earnings Yield

-13.24%

FCF Yield

-11.05%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

-$4.77

Next Year EPS Growth Estimate

$4.54

Next Year Revenue Growth Estimate

$1.56B

Return on Equity (ROE)

-43.96%

FREE CASH FLOW

Operating Margin

-3020.32%

Debt-to-Equity

0.05

Piotroski F-Score

2

Altman Z-Score

17.13

Return on Invested Capital (ROIC)

-41.03%

Current Ratio

18.60

Quick Ratio

18.56

Net Debt to EBITDA

0.12

Interest Coverage

0.00

Gross Profit margin

98.89%

FCF PER SHARE

$-4.03

REVENUE PER SHARE

$0.17

Analyze CRNX on TradingView

Gainseekers Quantitative Analysis

Summary

CRNX Crinetics Pharmaceuticals, Inc. presents a perplexing valuation scenario. Despite a staggering negative DCF Value, the market has priced the stock significantly above this metric, suggesting a disconnect or speculative optimism. The Forward P/E of 8.35 indicates potential growth, yet the negative Earnings Yield and ROIC highlight ongoing profitability challenges. However, the Altman Z-score of 17.90 suggests financial stability, offering a paradox of safety amidst operational turmoil. This stock is a high-risk, high-reward play, with the market seemingly betting on a turnaround.

AI Exposure / Tech Reliance

Operating in the Biotechnology sector, CRNX is well-positioned to leverage AI advancements in drug discovery and personalized medicine. The industry's inherent reliance on cutting-edge technology aligns with modern shifts, potentially enhancing R&D efficiency. However, execution remains key to capitalizing on these technological opportunities.

The Bull Case

For the bullish investor, CRNX's low Debt/Equity ratio of 0.0489 and a robust Current Ratio of 18.60 signal a fortress-like balance sheet. Despite a negative FCF Yield, the company's ability to maintain liquidity and financial flexibility is noteworthy. The Piotroski F-Score of 2 is low, but the gross profit margin of 98.89% suggests strong pricing power. This could appeal to GARP investors banking on future profitability and capital efficiency improvements.

The Bear Case

The bear case for CRNX is glaringly evident in its astronomical Price/Sales ratio of 218.71 and a Price/Book of 3.05, indicating severe overvaluation. The company's negative Operating Margin of -3020.32% and ROE of -43.96% underscore deep structural inefficiencies. With an EPS of -$4.77, the path to profitability is fraught with challenges. The stock's distance from its 52-week high suggests recent market skepticism, further amplifying the risk of holding this biotech player.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$85.83

Institutional Ownership %

1-Year Beta

0.28

Insider Buying % (6 Mo)

Distance to 52-Week High

61.04%

Distance to 52-Week Low

28.27%

EARNINGS SURPRISE %

-0.82%

50-DAY SMA

$37.78

200-DAY SMA

$41.43

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.